EEC Regulatory DocumentNote for guidance: Guidelines for minimizing the risk of transmitting agents causing spongiform encephalopathy via medicinal products**,*
References (6)
- et al.
Vet Pathol
(1980) - et al.
J Infect Dis
(1982)
There are more references available in the full text version of this article.
Cited by (35)
From vaccine manufacturing to its availability in pharmacy
2018, Revue des Maladies RespiratoiresNatural history of human transmissible subacute spongiform encephalopathies
1994, Transfusion clinique et biologiqueBiological properties of a thermally crosslinked gelatin film as a novel anti-adhesive material: Relationship between the biological properties and the extent of thermal crosslinking
2015, Journal of Biomedical Materials Research - Part B Applied BiomaterialsSafety evaluation of products derived from mammalian cell lines
2011, Mammalian Cell Biotechnology in Protein ProductionPrevention of Prion diseases in the production of medicinal products, medical devices, and cosmetics
2009, Prions in Humans and Animals
- **
This paper is covered by EC copyright. It is published with the agreement of the Office of EC Publications.
- *
Final approval of the document by CPMP 11 December 1991. Proposed date for coming into operation, 1 May 1992.
Copyright © 1992 Published by Elsevier Ltd.